Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Metformin  COVID-19 treatment studies for Metformin  C19 studies: Metformin  Metformin   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality 61% Improvement Relative Risk Crouse et al. Metformin for COVID-19 Prophylaxis Is prophylaxis with metformin beneficial for COVID-19? Retrospective 220 patients in the USA Lower mortality with metformin (p=0.021) Crouse et al., Front. Endocrinol., doi:10.3389/fendo.2020.600439 Favors metformin Favors control
Metformin Use Is Associated With Reduced Mortality in a Diverse Population With COVID-19 and Diabetes
Crouse et al., Front. Endocrinol., doi:10.3389/fendo.2020.600439
Crouse et al., Metformin Use Is Associated With Reduced Mortality in a Diverse Population With COVID-19 and Diabetes, Front. Endocrinol., doi:10.3389/fendo.2020.600439
Jan 2021   Source   PDF  
  All Studies   Meta
Retrospective 219 COVID-19+ diabetes patients in the USA, showing lower mortality with existing metformin treatment.
risk of death, 60.8% lower, RR 0.39, p = 0.02, treatment 8 of 76 (10.5%), control 34 of 144 (23.6%), NNT 7.6, adjusted per study, odds ratio converted to relative risk, multiple logistic regression.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Crouse et al., 13 Jan 2021, retrospective, USA, peer-reviewed, 6 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperMetforminAll
Abstract: ORIGINAL RESEARCH published: 13 January 2021 doi: 10.3389/fendo.2020.600439 Metformin Use Is Associated With Reduced Mortality in a Diverse Population With COVID-19 and Diabetes Andrew B. Crouse 1, Tiffany Grimes 2, Peng Li 3, Matthew Might 1, Fernando Ovalle 2 and Anath Shalev 2* 1 Hugh Kaul Precision Medicine Institute, University of Alabama at Birmingham, Birmingham, AL, United States, Comprehensive Diabetes Center, Department of Medicine, Division of Endocrinology, Diabetes and Metabolism, University of Alabama at Birmingham, Birmingham, AL, United States, 3 School of Nursing, University of Alabama at Birmingham, Birmingham, AL, United States 2 Edited by: Hans Ulrich Häring, Tübingen University Hospital, Germany Reviewed by: Abdurezak Ahmed Abdela, Addis Ababa University, Ethiopia Mohd Ashraf Ganie, Sher-I-Kashmir Institute of Medical Sciences, India *Correspondence: Anath Shalev Specialty section: This article was submitted to Clinical Diabetes, a section of the journal Frontiers in Endocrinology Received: 30 August 2020 Accepted: 07 December 2020 Published: 13 January 2021 Citation: Crouse AB, Grimes T, Li P, Might M, Ovalle F and Shalev A (2021) Metformin Use Is Associated With Reduced Mortality in a Diverse Population With COVID-19 and Diabetes. Front. Endocrinol. 11:600439. doi: 10.3389/fendo.2020.600439 Background: Coronavirus disease-2019 (COVID-19) is a growing pandemic with an increasing death toll that has been linked to various comorbidities as well as racial disparity. However, the specific characteristics of these at-risk populations are still not known and approaches to lower mortality are lacking. Methods: We conducted a retrospective electronic health record data analysis of 25,326 subjects tested for COVID-19 between 2/25/20 and 6/22/20 at the University of Alabama at Birmingham Hospital, a tertiary health care center in the racially diverse Southern U.S. The primary outcome was mortality in COVID-19-positive subjects and the association with subject characteristics and comorbidities was analyzed using simple and multiple linear logistic regression. Results: The odds ratio of contracting COVID-19 was disproportionately high in Blacks/ African-Americans (OR 2.6; 95% CI 2.19–3.10; p<0.0001) and in subjects with obesity (OR 1.93; 95% CI 1.64–2.28; p<0.0001), hypertension (OR 2.46; 95% CI 2.07–2.93; p<0.0001), and diabetes (OR 2.11; 95% CI 1.78–2.48; p<0.0001). Diabetes was also associated with a dramatic increase in mortality (OR 3.62; 95% CI 2.11–6.2; p<0.0001) and emerged as an independent risk factor in this diverse population even after correcting for age, race, sex, obesity, and hypertension. Interestingly, we found that metformin treatment prior to diagnosis of COVID-19 was independently associated with a significant reduction in mortality in subjects with diabetes and COVID-19 (OR 0.33; 95% CI 0.13– 0.84; p=0.0210). Conclusion: Thus, these results suggest that while diabetes is an independent risk factor for COVID-19-related mortality, this risk is dramatically reduced in subjects taking metformin prior to diagnosis of COVID-19, raising the possibility that metformin may provide a protective approach in this high risk population. Keywords: African-American, coronavirus disease-2019, diabetes, metformin, mortality Frontiers in Endocrinology | 1 January 2021 | Volume 11 | Article 600439 Crouse et al. Metformin Reduced COVID-19 Mortality analysis. This may have been due to..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop